Literature DB >> 17906879

Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera.

Robert W Evans1, Roozina Rafique, Adel Zarea, Chiara Rapisarda, Richard Cammack, Patricia J Evans, John B Porter, Robert C Hider.   

Abstract

Despite its importance in iron-overload diseases, little is known about the composition of plasma non-transferrin-bound iron (NTBI). Using 30-kDa ultrafiltration, plasma from thalassemic patients consisted of both filterable and non-filterable NTBI, the filterable fraction representing less than 10% NTBI. Low filterability could result from protein binding or NTBI species exceeding 30 kDa. The properties of iron citrate and its interaction with albumin were therefore investigated, as these represent likely NTBI species. Iron permeated 5- or 12-kDa ultrafiltration units completely when complexes were freshly prepared and citrate exceeded iron by tenfold, whereas with 30-kDa ultrafiltration units, permeation approached 100% at all molar ratios. A g = 4.3 electron paramagnetic resonance signal, characteristic of mononuclear iron, was detectable only with iron-to-citrate ratios above 1:100. The ability of both desferrioxamine and 1,2-dimethyl-3-hydroxypyridin-4-one to chelate iron in iron citrate complexes also increased with increasing ratios of citrate to iron. Incremental molar excesses of citrate thus favour the progressive appearance of chelatable lower molecular weight iron oligomers, dimers and ultimately monomers. Filtration of iron citrate in the presence of albumin showed substantial binding to albumin across a wide range of iron-to-citrate ratios and also increased accessibility of iron to chelators, reflecting a shift towards smaller oligomeric species. However, in vitro experiments using immunodepletion or absorption of albumin to Cibacron blue-Sepharose indicate that iron is only loosely bound in iron citrate-albumin complexes and that NTBI is unlikely to be albumin-bound to any significant extent in thalassemic sera.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906879     DOI: 10.1007/s00775-007-0297-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  25 in total

1.  Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

Authors:  W Breuer; M J Ermers; P Pootrakul; A Abramov; C Hershko; Z I Cabantchik
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

Review 2.  Iron and citric acid: a fuzzy chemistry of ubiquitous biological relevance.

Authors:  J L Pierre; I Gautier-Luneau
Journal:  Biometals       Date:  2000-03       Impact factor: 2.949

3.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Authors:  J B Porter; R D Abeysinghe; L Marshall; R C Hider; S Singh
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

4.  New trends in the chemistry of iron(III) citrate complexes: correlations between X-ray structures and solution species probed by electrospray mass spectrometry and kinetics of iron uptake from citrate by iron chelators.

Authors:  Isabelle Gautier-Luneau; Claire Merle; Delphine Phanon; Colette Lebrun; Frédéric Biaso; Guy Serratrice; Jean-Louis Pierre
Journal:  Chemistry       Date:  2005-03-18       Impact factor: 5.236

Review 5.  Ribonucleotide reductase, lipoxygenase and the intracellular low-molecular-weight iron pool.

Authors:  C E Cooper; J B Porter
Journal:  Biochem Soc Trans       Date:  1997-02       Impact factor: 5.407

6.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy.

Authors:  M Grootveld; J D Bell; B Halliwell; O I Aruoma; A Bomford; P J Sadler
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

7.  Non-transferrin-bound iron induced by myeloablative chemotherapy.

Authors:  S J Bradley; I Gosriwitana; S Srichairatanakool; R C Hider; J B Porter
Journal:  Br J Haematol       Date:  1997-11       Impact factor: 6.998

8.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

Authors:  P Brissot; T L Wright; W L Ma; R A Weisiger
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy.

Authors:  O I Aruoma; A Bomford; R J Polson; B Halliwell
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

10.  Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Authors:  Breno P Esposito; William Breuer; Pornpan Sirankapracha; Pensri Pootrakul; Chaim Hershko; Z Ioav Cabantchik
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  43 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Authors:  Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

4.  Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation.

Authors:  Eldad A Hod; Ning Zhang; Set A Sokol; Boguslaw S Wojczyk; Richard O Francis; Daniel Ansaldi; Kevin P Francis; Phyllis Della-Latta; Susan Whittier; Sujit Sheth; Jeanne E Hendrickson; James C Zimring; Gary M Brittenham; Steven L Spitalnik
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

5.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

6.  The influence of storage age on iron status, oxidative stress and antioxidant protection in paediatric packed cell units.

Authors:  Keith Collard; Desley White; Adrian Copplestone
Journal:  Blood Transfus       Date:  2013-11-29       Impact factor: 3.443

7.  Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes.

Authors:  Yuichi Baba; Jason K Higa; Briana K Shimada; Kate M Horiuchi; Tomohiro Suhara; Motoi Kobayashi; Jonathan D Woo; Hiroko Aoyagi; Karra S Marh; Hiroaki Kitaoka; Takashi Matsui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-11-10       Impact factor: 4.733

Review 8.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

9.  Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

Authors:  Ashutosh Lal; John Porter; Nancy Sweeters; Vivian Ng; Patricia Evans; Lynne Neumayr; Gregory Kurio; Paul Harmatz; Elliott Vichinsky
Journal:  Blood Cells Mol Dis       Date:  2012-11-11       Impact factor: 3.039

10.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.